Rocket Lab's High-Stakes August: A Stock Down 57% From Its Peak, Yet the Backlog Keeps Growing
Published on 08/01/2026 at 23:03 | Redaktion boerse-global.de
The numbers tell two conflicting stories about Rocket Lab right now. One is a company firing on all cylinders—record contracts, a landmark government deal, and a launch vehicle that keeps winning customers. The other is a chart that has shed more than a third of its value in a single month, leaving shareholders nursing losses that bear little resemblance to the operational momentum underneath.
When the company reports second-quarter earnings on August 10, the options market is bracing for fireworks: traders have priced in a 17 percent swing, well above the roughly 10.4 percent average move the stock has historically made after quarterly reports. Analysts are looking for a loss of $0.06 per share on revenue of $231.62 million—growth of about 60 percent from the same period last year.
A Market That's Moved On
The stock closed the week at €56.30, barely budging from recent levels. That surface calm masks a brutal stretch: over the past 30 trading days, shares have fallen 36.02 percent, and they now sit 57.92 percent below the 52-week high of €133.80 set on May 27. The stock is trading beneath both its 50-day moving average of €83.36 and its 200-day average of €67.37, with an RSI of 36.7 signaling oversold territory—though without a clear reversal signal yet.
Part of the explanation lies beyond Rocket Lab's own walls. The broader space sector has cooled considerably since SpaceX's June IPO, which has shed roughly half its valuation. As the most liquid pure-play proxy for the industry, Rocket Lab has absorbed much of that de-rating even as its own order book expands. Investor anxiety about potential dilution from future capital raises has added to the pressure.
Should investors sell immediately? Or is it worth buying Rocket Lab?
The annualized volatility of nearly 96 percent tells its own story—this is a stock that swings like a pre-revenue biotech, not a company approaching $680 million in annual sales. Over twelve months, shares are still up 39 percent, but 2026 has been a year of profit-taking after 2025's rally, with the stock down 8.46 percent year-to-date.
The Neutron Question
At the heart of the volatility sits a single structural question: Can Rocket Lab get the Neutron rocket off the ground on schedule? Management has committed to a first flight in the fourth quarter of 2026, and the backlog for the vehicle is filling fast—five firm commercial missions are already booked before the inaugural launch. A successful recent test is seen as an important milestone on that path, though the program has faced setbacks this year, including the loss of components intended for the first flight.
The gap between contract wins and hardware readiness is widening. Rocket Lab's backlog stood at $2.2 billion as of the first quarter, backed by more than $2 billion in available liquidity—a cushion that has kept technical sell-offs from turning into balance-sheet panic.
Electron and the Government Keep the Engine Running
While Neutron works through qualification testing, the proven Electron rocket and government contracts are doing the revenue heavy lifting. Electron has been on a record pace since the start of the year, adding 36 new launch contracts in the first quarter alone.
The U.S. Space Force has become a particularly valuable customer. Rocket Lab was selected alongside 14 other companies—including Firefly Aerospace and Boeing—for a potential program worth $981 million. Days earlier, the company secured a $266 million contract with the Space Force for twelve suborbital missions from the Kodiak launch site in Alaska, with options for six additional launches through 2028. It's the largest government award in company history, and it has kept analysts constructive despite the weak chart: Bank of America raised its price target on the news, with Roth Capital, Citizens, and New Street Research following suit with higher marks or fresh coverage.
The backlog math is compelling. Rocket Lab ended 2025 with revenue of $602 million, up 38 percent, and first-quarter 2026 revenue of $200.3 million represented 63 percent growth. In July, the company signed another multi-launch deal with Japanese Earth-observation provider iQPS—three additional Electron missions starting in late 2027, bringing the total contracted launches for iQPS to 18. Each mission will carry a QPS-SAR satellite to a 575-kilometer orbit, using Rocket Lab's Motorized Lightband separation system. Electron has already delivered seven satellites for this constellation since 2023 with a perfect success record.
The Iridium Bet
The biggest catalyst on the horizon is the roughly $8 billion acquisition of satellite operator Iridium Communications, expected to close in mid-2027. The deal's logic is straightforward: Iridium generated $93 million in profit and $288 million in free cash flow over the past twelve months, while Rocket Lab posted a net loss of $183 million and negative cash flow of $316 million. Combined, projections from Motley Fool suggest a net profit of $137 million and free cash flow of $425 million in 2027—the first sustained profitability for the merged entity.
Rocket Lab at a turning point? This analysis reveals what investors need to know now.
Analysts Split, Institutions Mixed
Wall Street's views diverge sharply. Citizens analyst Trevor Walsh reaffirmed his buy rating with a $130 price target, while KeyCorp upgraded the stock to Overweight with a $135 target. The consensus price target sits at $110.29 with a Moderate Buy rating—still more than 76 percent above the current price, a discrepancy rarely seen for a company posting its best operational year.
Institutional moves tell a similarly mixed story. Dimensional Fund Advisors cut its stake by 8.1 percent in the first quarter, while Vanguard added 13.4 percent and Baillie Gifford expanded its position by 47.2 percent.
For investors, August 10 looms as the next major test. Between the swelling backlog, the Iridium wager, and a heavily priced-in earnings swing, the upcoming report is shaping up as one of the most consequential dates on the calendar for the stock this year. As one analyst put it, one side of this trade is "massively wrong"—the question is which one. The answer may not come from an earnings call, but from a test stand in Virginia, where Neutron's fate—and arguably the stock's—will ultimately be decided.
Ad
Rocket Lab Stock: New Analysis - 1 August
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
